Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0KJHLZ)
| ADC Name |
IBI3001
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
IBI3001
Click to Show/Hide
|
|||||
| Organization |
Innovent Biologics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
IBI-334
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen; Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
2027 Update
General Information of The ADMET Data Related to This ADC
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 282 | h |
IBI3001 has a favorable PK profile in BALB/c mice with the half-life at 282 hours.
|
[1] |
References